Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.

Cell cycle (Georgetown, Tex.) - 1 Jan 2014

Menendez Javier A, Alarcón Tomás, Joven Jorge

Abstract excerpt

Oncometabolites are defined as small-molecule components (or enantiomers) of normal metabolism whose accumulation causes signaling dysregulation to establish a milieu that initiates carcinogenesis. In a similar manner, we propose the term "gerometabolites" to refer to small-molecule components of normal metabolism whose depletion causes signaling dysregulation to establish a milieu that drives aging. In an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Hypoxia
Share to Cellular Reprogramming
Share to Fumarate Hydratase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fumarates

Share to Glutarates

Share to Hypoxia-Inducible Factor 1

Share to Succinates

Source

Open in PubMed Open full text

Identifiers

PMID: 24526120
DOI: 10.4161/cc.28079
PMCID: PMC3979906

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.PMID 24526120Read ↗

2-Hydroxyglutarate in Cancer Cells.Semantic proximity Read ↗

Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human diseaseSemantic proximity Read ↗

Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.Semantic proximity Read ↗

Metabolic Rewiring in the Face of Genomic Assault: Integrating DNA Damage Response and Cellular MetabolismSemantic proximity Read ↗

Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.Semantic proximity Read ↗

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.Semantic proximity Read ↗

Knowledge-Based Therapeutics for Tricarboxylic Acid (TCA) Cycle-Deficient Cancers.Semantic proximity Read ↗

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.Semantic proximity Read ↗

Redox Homeostasis and Beyond: The Role of Wild-Type Isocitrate Dehydrogenases for the Pathogenesis of Glioblastoma.Semantic proximity Read ↗

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.Semantic proximity Read ↗

Metabolic syndromes and malignant transformation: where the twain shall meet.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.